Forty Seven, Inc., a Menlo Park, CA-based clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, received $6m in funding.
The Leukemia & Lymphoma Society (LLS) provided the financial resources.
The company intends to use the funds to accelerate the development of 5F9 in Myelodysplastic Syndrome.
Led by Mark McCamish, M.D., Ph.D., President & Chief Executive Officer, Lee Greenberger, Ph.D., chief scientific officer, Mukul Agarwal, VP Corporate Development, and Mark Chao, M.D., Ph.D., Co-founder and VP Clinical Development, Forty Seven is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University.
The company’s lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a “don’t eat me” signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in multiple clinical studies in patients with solid tumors, myelodysplastic syndrome, acute myeloid leukemia, non-Hodgkin’s lymphoma, ovarian cancer and colorectal carcinoma.